atipamezole has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagińska, M; Barut, J; Chmielarz, P; Daniel, WA; Kot, M; Kreiner, G; Nalepa, I; Parlato, R; Rafa-Zabłocka, K | 1 |
| Bhide, N; Bishop, C; Conti, M; George, JA; Hallmark, J; Ostock, CY; Palumbo, N | 1 |
2 other study(ies) available for atipamezole and Parkinsonian Disorders
| Article | Year |
|---|---|
Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism.
Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopaminergic Neurons; Female; Imidazoles; Immunohistochemistry; Locus Coeruleus; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Reboxetine; Substantia Nigra; Ventral Tegmental Area | 2019 |
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clonidine; Dyskinesia, Drug-Induced; Imidazoles; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 2015 |